Amneal Pharmaceuticals
AMRX
160 hedge funds and large institutions have $512M invested in Amneal Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 53 increasing their positions, 50 reducing their positions, and 27 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 50
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 161 → 160 (-1)
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
5% less call options, than puts
Call options by funds: $1.57M | Put options by funds: $1.66M
1.23% less ownership
Funds ownership: 68.44% → 67.22% (-1.2%)
25% less capital invested
Capital invested by funds: $684M → $512M (-$172M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$4.94M |
| 2 |
Millennium Management
New York
|
+$3.21M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.65M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
+$2.56M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.29M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$4.92M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.85M |
| 4 |
Two Sigma Investments
New York
|
-$3.62M |
| 5 |
BlackRock
New York
|
-$3.25M |
AMRX Hedge Fund Activity: Q2 2021 in Review
160 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2021, worth a combined $512M — down 25% from $684M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of AMRX and 26 opened new positions — a net loss of 1 holder — while 50 trimmed existing stakes and 53 added.
The largest buyer was Eversept Partners, adding an estimated $4.94M. The largest seller was Point72 Asset Management, cutting an estimated $6.29M.
- 160 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2021, down from 161 in Q1 2021.
- Funds reported $512M of Amneal Pharmaceuticals stock for Q2 2021, down 25% quarter-over-quarter.
- 26 funds opened new Amneal Pharmaceuticals positions in Q2 2021 and 27 closed out, a net change of -1 holder.
- The largest Amneal Pharmaceuticals buyer in Q2 2021 was Eversept Partners, an estimated $4.94M added.
- The largest Amneal Pharmaceuticals seller in Q2 2021 was Point72 Asset Management, an estimated $6.29M sold.
Based on aggregated 13F filings for Q2 2021.